

Bivalent booster effectiveness against severe COVID-19 outcomes in Finland, September 2022 – March 2023

Eero Poukka^{1,2}, Hanna Nohynek¹, Sirkka Goebeler³, Tuija Leino¹, Ulrike Baum¹

1. Infectious Disease Control and Vaccinations Unit, Department of Health Security, Finnish Institute for Health and Welfare, Mannerheimintie 166, 00300 Helsinki, Finland
2. Department of Public Health, Faculty of Medicine, University of Helsinki, Yliopistonkatu 4, 00100 Helsinki, Finland
3. Forensic Medicine Unit, Department of Government services, Finnish Institute for Health and Welfare, Mannerheimintie 166, 00300 Helsinki, Finland

12 **Abstract**

13 Bivalent COVID-19 vaccines were introduced in 2022 but knowledge of their effectiveness against severe
14 COVID-19 outcomes is currently limited. In Finnish register-based cohort analyses, we compared the risk of
15 severe COVID-19 outcomes among those who received bivalent vaccination (exposed) between September
16 2022 and March 2023 to those who did not (unexposed). Among elderly aged 65–110 years, bivalent
17 vaccination reduced the risk of hospitalisation and death due to COVID-19 in September–December 2022;
18 the hazard ratios comparing exposed and unexposed ranged from 0.37 to 0.45 during the first 31–60 days
19 since bivalent vaccination. However, in January–March 2023 the effect disappeared possibly indicating
20 immune evasion of new SARS-CoV-2 variants, waning of vaccine effectiveness and increased presence of
21 hybrid immunity. Among the chronically ill aged 18–64 years bivalent vaccination did not reduce the risk of
22 severe COVID-19 outcomes. These results are important for developing COVID-19 vaccines and
23 programmes worldwide.

24

25 **Main text**

26 Due to the emergence of new SARS-CoV-2 variants with immune evasive capabilities¹, new, bivalent COVID-
27 19 vaccines, containing mRNA that encodes the spike proteins of the original virus strain and the Omicron
28 variant, were developed in 2022. The European Medicines Agency authorized the first (BA.1 and BA.4-5)
29 bivalent vaccines in September 2022^{2,3}, which were promptly recommended in Finland as a booster for all
30 people aged 65 years or more and those aged 18–64 years with underlying medical conditions predisposing
31 to severe COVID-19.

32 In previous studies, bivalent vaccines have increased the protection against severe outcomes^{4–11}. However,
33 the duration of this protection is currently unclear; it is expected to vary by time since vaccination and
34 across different Omicron lineages. In studies conducted in United Kingdom and Canada, the effectiveness of
35 bivalent vaccines was slightly reduced against sublineage BQ.1^{9,12} and possibly even further reduced against
36 the sublineages CH.1.1 and XBB.1.5¹². Thus, studies estimating the effectiveness of bivalent vaccines over

37 time are needed as policy makers are considering the recommendation of a second bivalent booster.
38 Presently, policies vary between countries: some countries decided to recommend a second bivalent
39 booster¹³, while others do not yet recommend further boosters for spring 2023.

40 The aim of this study was to estimate the effectiveness of BA.1 and BA.4-5 bivalent COVID-19 vaccines
41 against severe COVID-19 outcomes up to five months after vaccination in Finland based on national register
42 data. Since bivalent boosters were primarily offered to individuals who had received at least two
43 monovalent doses, our study was restricted to these vaccinees. The study period was divided into two
44 subperiods, i.e., September–December 2022 and January–March 2023, to account for the change in
45 circulating Omicron lineages (Supplementary Figure S1). To control for confounding, all analyses were
46 adjusted for a set of potential confounders; a negative control outcome was used to assess the presence of
47 residual confounding.

48

49 **Results**

50 The study cohorts included 1,197,501 elderly aged 65–110 years and 444,327 chronically-ill individuals aged
51 18–64 years (Supplementary Table S3). Only a small proportion of each cohort had been laboratory-
52 confirmed SARS-CoV-2-positive prior to the study (Supplementary Table S4). The 2022–2023 influenza
53 vaccination coverage reached 58% in the elderly cohort and 37% in the chronically ill cohort.

54 During the study 645,861 (52%) elderly and 71,497 (15%) chronically ill were vaccinated with a bivalent
55 booster; approximately a third of them received Comirnaty BA.1 while the other two thirds received
56 Comirnaty BA.4-5. Spikevax bivalent vaccines were used only in small quantities. The median time since
57 bivalent vaccination by the end of follow-up was 133 days (interquartile range 116–143 days) and 128 days
58 (interquartile range 106–143 days) among the elderly and chronically ill, respectively.

59 Among the elderly, we observed altogether 2,013 hospitalisations due to COVID-19, 1,167 deaths due to
60 COVID-19 and 984 deaths in which COVID-19 was a contributing factor. In September–December 2022,

61 during the first 14–30 and 31–60 days since vaccination, a bivalent booster lowered the risk of
62 hospitalisation due to COVID-19 (hazard ratio [HR] 0.41, 95% confidence interval [CI] 0.31–0.55; HR 0.37,
63 95% CI 0.27–0.50), death due to COVID-19 (0.34, 0.23–0.66; 0.47, 0.33–0.66) and death in which COVID-19
64 was a contributing factor (0.40, 0.27–0.60; 0.45, 0.31–0.64) (Fig. 1, Supplementary Table S5). Thereafter, in
65 January–March 2023, the HRs were higher and ranged during days 31–150 between 0.71 (95% CI 0.46–
66 1.12) and 1.23 (0.79–1.91) for hospitalisation due to COVID-19, 0.75 (0.42–1.33) and 0.90 (0.44–1.87) for
67 death due to COVID-19, and 0.40 (0.24–0.67) and 1.30 (0.63–2.66) for death in which COVID-19 was a
68 contributing factor. Overall, in January–March 2023, the risk of severe COVID-19 outcomes was similar
69 between those who did and those who did not receive a bivalent booster at any time since vaccination.
70 When stratified by age, the CIs of the HRs were wide and broadly overlapping; in September–December
71 2022 the HRs for 65–79-year-olds and 80–110-year-olds were comparable (Fig. 2, Supplementary Tables S6–
72 7). Both BA.1 and BA.4–5 bivalent vaccines reduced the risk of severe COVID-19 outcomes; the HRs were
73 similar (Supplementary Table S8).

74 Among the chronically ill we observed altogether 278 hospitalisations due to COVID-19, 18 deaths due to
75 COVID-19 and 20 deaths in which COVID-19 was a contributing factor. In September–December 2022, the
76 HR of hospitalisation due to COVID-19 was 1.01 (95% CI 0.43–2.40) for days 14–30 since bivalent
77 vaccination and 1.81 (0.87–3.76) for the subsequent 30 days. In January–March 2023, that HR ranged
78 between 0.74 (95% CI 0.16–3.30) and 3.40 (1.34–8.66) during days 31–150. The HR for the other two
79 outcomes could not reliably be estimated (Supplementary Table S9).

80 In our negative control outcome analysis, we observed 16,577 emergency room visits due to injury among
81 the elderly and 3,765 such visits among the chronically ill. We found no major difference in the risk of injury
82 among elderly who received a bivalent booster and those who did not (Supplementary Table S5). However,
83 among the chronically ill who received a bivalent booster the risk of injury appeared slightly elevated
84 (Supplementary Table S9).

85

86 **Figure 1. Hazard ratios among the elderly.** Covariate-adjusted hazard ratios (with 95% confidence
87 intervals) comparing the hazards of severe COVID-19 outcomes in 65-to-110-year-olds who received a
88 bivalent COVID-19 vaccine with the corresponding hazards in those who did not receive a bivalent COVID-
89 19 vaccine, Finland.

90 **Figure 2. Age-stratified hazard ratios among the elderly.** Covariate-adjusted hazard ratios (with 95%
91 confidence intervals) comparing the hazards of severe COVID-19 outcomes in 65-to-110-year-olds who
92 received a bivalent COVID-19 vaccine with the corresponding hazards in those who did not receive a
93 bivalent COVID-19 vaccine stratified by age group, Finland.

94 Discussion

95 In our Finnish study, a bivalent booster reduced the risk of severe COVID-19 outcomes among the elderly in
96 September–December 2022. Furthermore, bivalent boosters were equally effective among individuals aged
97 65–79 years and those aged 80 years or more. However, a bivalent booster appeared to neither reduce the
98 risk of severe COVID-19 outcomes among the elderly in January–March 2023 nor benefit the chronically-ill
99 18–64-year-olds. For the interpretation of our findings, it is crucial to note that we estimated only the
100 incremental effect of bivalent boosters as the comparison was not done between vaccinated and
101 unvaccinated individuals.

102 We suggest three hypotheses for the reduced protective effect of bivalent boosters among elderly in
103 January–March 2023. Firstly, at the beginning of the study BA.5 was the predominant Omicron lineage in
104 Finland (Supplementary Figure S1), but in January–March 2023 SARS-CoV-2 infections were mostly caused
105 by the sublineages BQ.1, CH.1.1 and XBB.1.5, which have better immune evasive capabilities than BA.5^{14–17}
106 and have been associated with lower vaccine effectiveness estimates^{9,12}. In addition, immune imprinting
107 might have contributed to the lower protection levels observed in our study^{18,19}. Secondly, the waning of
108 effectiveness over time since vaccination, as observed in previous studies^{8–10,12}, might have negatively
109 affected the protection levels in January–March 2023. Because the potential effect of waning coincided
110 with the emergence of new sublineages, our study does not facilitate a clean estimation of the effect of
111 time since vaccination. To distinguish these two issues, other studies with access to viral sequencing data
112 are required. Thirdly, the prevalence of hybrid immunity in the study population increased during the study
113 period due to plenty of SARS-CoV-2 infections, which to a large but unknown proportion remained
114 unregistered and, thus, could not be numerically considered in the study. As hybrid immunity provides high
115 protection against severe COVID-19 outcomes²⁰, its increased prevalence might have attenuated the
116 additional benefit of a bivalent booster in our study by some margin.

117 If other studies also observe a notable reduction of bivalent vaccine effectiveness against severe COVID-19
118 outcomes caused by BQ.1, CH.1.1 and XBB.1.5, it signals the importance of updating the vaccine

119 composition. This has also major programmatic implications: It might lead to withdrawal of the current
120 BA.1 and BA.4-5 bivalent vaccines in the near future. Furthermore, it would suggest that COVID-19
121 vaccination campaigns must be constantly reviewed in the light of the ever-changing epidemic situation,
122 economic analyses and vaccine supply.

123 Among the chronically ill we did not observe bivalent vaccination to reduce the risk of severe COVID-19
124 outcomes, although previous studies have found a benefit among working-age adults⁶. This may be due to
125 several reasons. Firstly, only a small proportion of the cohort received a bivalent booster, and the negative
126 control outcome analysis indicated the presence of residual confounding. Secondly, individuals who did not
127 receive the booster might have had higher likelihood of unregistered SARS-CoV-2 infection and thus hybrid
128 immunity prior to the study, which could have led to underestimation of the effectiveness. Thirdly, the
129 number of cases among the chronically ill was small, which together with the low bivalent vaccine uptake
130 led to unprecise estimates for that group. Fourthly, a good baseline protection due to monovalent
131 vaccinations and hybrid immunity among the chronically ill might have limited the additional benefit of a
132 bivalent booster.

133 As another limitation, we observed a decreased risk of severe COVID-19 outcomes during the first 0–13
134 days since bivalent vaccination. This was probably caused by selection (i.e. healthy vaccinee) bias as
135 individuals with acute respiratory symptoms, a predeterminant of severe COVID-19 outcomes, were not
136 advised to seek vaccination. However, it should be noted that the effect of this bias diminishes over time
137 and is likely negligible after 13 or latest 30 days since vaccination.

138 Our study has also several strengths. The study was timely and representative. We used the monovalent
139 vaccinated as the reference group, whose characteristics are probably more like the characteristics of the
140 bivalent vaccinated compared to those of the unvaccinated. Furthermore, we did not observe major
141 residual confounding in the negative control outcome analysis among the elderly. The recording of
142 vaccinations and COVID-19 outcomes is mandatory, and the utilised registers have been well maintained as

143 they have been used for routine surveillance of the COVID-19 vaccination programme and the COVID-19
144 pandemic in Finland.

145 In conclusion, bivalent boosters reduced the risk of hospitalisation and death due to COVID-19 in
146 September–December 2022 among the elderly who had previously received at least two monovalent doses
147 but not in January–March 2023 possibly indicating immune evasion of new SARS-CoV-2 variants, waning of
148 vaccine effectiveness and increased presence of hybrid immunity. We did not observe an additional benefit
149 of bivalent boosters among chronically-ill 18–64-year-olds. These findings have major vaccine development
150 and programmatic implications, such as a need for updated COVID-19 vaccines and a refined selection of
151 subpopulations targeted by future vaccination campaigns.

152

153 **References**

- 154 1. Qu, P. *et al.* Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5
155 Subvariants. *N Engl J Med* **387**, 1329–1331 (2022).
- 156 2. EMA. First adapted COVID-19 booster vaccines recommended for approval in the EU. *European*
157 *Medicines Agency* [https://www.ema.europa.eu/en/news/first-adapted-covid-19-booster-vaccines-](https://www.ema.europa.eu/en/news/first-adapted-covid-19-booster-vaccines-recommended-approval-eu)
158 [recommended-approval-eu](https://www.ema.europa.eu/en/news/first-adapted-covid-19-booster-vaccines-recommended-approval-eu) (2022).
- 159 3. EMA. Adapted vaccine targeting BA.4 and BA.5 Omicron variants original SARS-CoV-2 recommended for
160 approval. *European Medicines Agency* [https://www.ema.europa.eu/en/news/adapted-vaccine-](https://www.ema.europa.eu/en/news/adapted-vaccine-targeting-ba4-ba5-omicron-variants-original-sars-cov-2-recommended-approval)
161 [targeting-ba4-ba5-omicron-variants-original-sars-cov-2-recommended-approval](https://www.ema.europa.eu/en/news/adapted-vaccine-targeting-ba4-ba5-omicron-variants-original-sars-cov-2-recommended-approval) (2022).
- 162 4. Andersson, N. W. *et al.* *Comparative effectiveness of the bivalent BA.4-5 and BA.1 mRNA-booster*
163 *vaccines in the Nordic countries*. <http://medrxiv.org/lookup/doi/10.1101/2023.01.19.23284764> (2023)
164 [doi:10.1101/2023.01.19.23284764](https://doi.org/10.1101/2023.01.19.23284764).
- 165 5. Tenforde, M. W. *et al.* Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–
166 Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among

- 167 Immunocompetent Adults — VISION Network, Nine States, September–November 2022. *MMWR Morb.*
168 *Mortal. Wkly. Rep.* **71**, 1616–1624 (2022).
- 169 6. Surie, D. *et al.* Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–
170 Associated Hospitalization Among Immunocompetent Adults Aged ≥ 65 Years — IVY Network, 18 States,
171 September 8–November 30, 2022. *MMWR Morb. Mortal. Wkly. Rep.* **71**, 1625–1630 (2022).
- 172 7. Fabiani, M. *et al.* Protection against severe COVID-19 after second booster dose of adapted bivalent
173 (original/Omicron BA.4-5) mRNA vaccine in persons ≥ 60 years, by time since infection, Italy, 12
174 September to 11 December 2022. *Eurosurveillance* **28**, (2023).
- 175 8. Møller Kirsebom, F. C., Andrews, N., Stowe, J., Ramsay, M. & Bernal, J. L. *Long-term duration of*
176 *protection of ancestral-strain monovalent vaccines and effectiveness of the bivalent BA.1 boosters*
177 *against COVID-19 hospitalisation during a period of BA.5, BQ.1, CH.1.1. and XBB.1.5 circulation in*
178 *England.* <http://medrxiv.org/lookup/doi/10.1101/2023.03.31.23288018> (2023)
179 doi:10.1101/2023.03.31.23288018.
- 180 9. Grewal, R. *et al.* *Effectiveness of mRNA COVID-19 monovalent and bivalent vaccine booster doses against*
181 *Omicron severe outcomes among adults aged ≥ 50 years in Ontario, Canada.*
182 <http://medrxiv.org/lookup/doi/10.1101/2023.04.11.23288403> (2023)
183 doi:10.1101/2023.04.11.23288403.
- 184 10. Lin, D.-Y. *et al.* Durability of Bivalent Boosters against Omicron Subvariants. *N Engl J Med*
185 *NEJMc2302462* (2023) doi:10.1056/NEJMc2302462.
- 186 11. Arbel, R. *et al.* Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19
187 outcomes: a retrospective cohort study. *The Lancet Infectious Diseases* S1473309923001226 (2023)
188 doi:10.1016/S1473-3099(23)00122-6.
- 189 12. UK Health Security Agency. COVID-19 vaccine surveillance report: week 14.
- 190 13. Folkhälsomyndigheten. Fortsatt vaccination mot covid-19 under 2023 för personer 65 år och äldre samt
191 för yngre med riskfaktorer — Folkhälsomyndigheten. <https://www.folkhalsomyndigheten.se/nyheter->

192 och-press/nyhetsarkiv/2022/december/fortsatt-vaccination-mot-covid-19-under-2023-for-personer-65-
193 ar-och-aldre-samt-for-yngre-med-riskfaktorer/ (2022).

194 14. Uriu, K. *et al.* Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron
195 XBB.1.5 variant. *The Lancet Infectious Diseases* **23**, 280–281 (2023).

196 15. Miller, J. *et al.* Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1. *N*
197 *Engl J Med* **388**, 662–664 (2023).

198 16. Lasrado, N. *et al.* Waning Immunity Against XBB.1.5 Following Bivalent mRNA Boosters.
199 <http://biorxiv.org/lookup/doi/10.1101/2023.01.22.525079> (2023) doi:10.1101/2023.01.22.525079.

200 17. Qu, P. *et al.* Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and
201 CA.3.1 variants. *Cell Reports* **42**, 112443 (2023).

202 18. Zhou, Z., Barrett, J. & He, X. Immune Imprinting and Implications for COVID-19. *Vaccines* **11**, 875 (2023).

203 19. Offit, P. A. Bivalent Covid-19 Vaccines — A Cautionary Tale. *N Engl J Med* **388**, 481–483 (2023).

204 20. Bobrovitz, N. *et al.* Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity
205 against the omicron variant and severe disease: a systematic review and meta-regression. *The Lancet*
206 *Infectious Diseases* **23**, 556–567 (2023).

207 21. Baum, U. *et al.* Effectiveness of vaccination against SARS-CoV-2 infection and Covid-19 hospitalisation
208 among Finnish elderly and chronically ill—An interim analysis of a nationwide cohort study. *PLoS ONE*
209 **16**, e0258704 (2021).

210

211 **Authors' contributions.** EP, UB, HN and TL conceptualised the study. UB conducted the statistical analysis
212 and SG provided the death certificate data. EP and HN reviewed the literature. EP and UB drafted the
213 manuscript. EP, UB, SG HN and TL gave comments and revised the manuscript.

214 **Conflict of interests.** HN is a member of Finnish National Immunization Technical Advisory Groups and
215 chairman of Strategic Advisory Group of Experts on Immunization for World Health Organization.

216 **Funding.** EP received a grant from The Finnish Medical Foundation. No other sources of external funding.

217 **Research ethics.** By Finnish law, the Finnish Institute for Health and Welfare (THL) is the national expert
218 institution to carry out surveillance on the impact of vaccinations in Finland (Communicable Diseases Act,
219 <https://www.finlex.fi/en/laki/kaannokset/2016/en20161227.pdf>). Neither specific ethical approval of this
220 study nor informed consent from the participants was needed.

221 **Data availability.** By Finnish law, the authors are not permitted to share individual-level register data. The
222 computing code is available upon request.

223 **Acknowledgements.** We thank Erika Lindh and Aapo Juutinen for providing Supplementary Figure 1 as well
224 as Heini Salo and Toni Lehtonen for the register-based identification of individuals with medical conditions
225 predisposing to severe COVID-19. Additional thanks go to all the colleagues at the Finnish Institute for
226 Health and Welfare (THL) who curate the register data. Lastly, we are grateful for our fruitful collaboration
227 with Statistics Finland.

228

229 **Online Methods**

230 We conducted population-based cohort analyses linking national register data from Finland using a unique
231 person identifier. The study period was from 1 September 2022 to 31 March 2023, when various
232 sublineages of Omicron were the dominant SARS-CoV-2 strains (Supplementary Figure S1). In analogy to
233 our previous study²¹, we formed two cohorts of individuals aged 65 years or more (the elderly) and
234 individuals aged 18–64 years with comorbidities or medical therapies predisposing to severe COVID-19 (the
235 chronically ill, Supplementary Tables S1-2). We included only individuals that had received at least two
236 monovalent COVID-19 vaccine doses (Comirnaty/ tozinameran/ BNT162b2, Spikevax/ elasomeran/ mRNA-
237 1273, or Vaxzevria/ ChAdOx1-SARS-COV-2/ AZD1222). In addition, we excluded individuals that were
238 hospitalised due to COVID-19 at the beginning of the study or had received a COVID-19 vaccination with too
239 short dosing interval or a bivalent vaccination prior to the study (Supplementary Table S3).

240 The exposure was defined as vaccination with a BA.1 or BA.4-5 bivalent vaccine recorded in the Finnish
241 Vaccination Register and was time-dependently categorized into seven groups: not vaccinated with a
242 bivalent booster (the reference), and 0–13, 14–30, 31–60, 61–90, 91–120, 121–150, 151–180 and 181 or
243 more days since vaccination with a bivalent booster. The bivalent vaccines included in this study were
244 either based on Comirnaty or Spikevax as other bivalent vaccines were not available in Finland during the
245 study period.

246 The severe COVID-19 outcomes were hospitalisation due to COVID-19, death due to COVID-19 and death in
247 which COVID-19 was a contributing factor. Hospitalisations, recorded in the Care Register for Health Care,
248 had to fulfil the following two criteria to be considered as hospitalisations due to COVID-19:

- 249 1) The primary diagnosis was COVID-19 (International Classification of Diseases, 10th revision: U07.1,
250 U07.2), acute respiratory tract infection (J00– J22, J46) or severe complication of lower respiratory
251 tract infections (J80–84, J85.1, J86).

252 2) A positive PCR- or antigen SARS-CoV-2 sample was taken from the hospitalized patient in the period
253 extending from 14 days before to 7 days after hospital admission and registered in the National
254 Infectious Diseases Register.

255 To define the two COVID-19 death outcomes, we used data collected from death certificates. In Finland,
256 physicians record the cause of death of their patients as well as other significant conditions contributing to
257 death in death certificates that are thereafter reviewed by medico-legal specialists at the Finnish Institute
258 for Health and Welfare prior to forming statistics. In our study, death due to COVID-19 included all deaths
259 in which COVID-19 was recorded as the cause of death in the death certificate. The cases in which COVID-
260 19 was a contributing factor to death were equally retrieved from the death certificates. For the study, the
261 data from reviewed death certificates were computerized into a database by medico-legal specialists
262 accepting the ICD10 codes U07.1, U07.2, U09, and U10 as COVID-19 diagnosis.

263 In addition, we defined a fourth endpoint, which we assumed to be unaffected by the exposure. This
264 negative control outcome was any emergency room visit due to injury (International Classification of
265 Diseases, 10th revision: S00–T14) recorded in the Care Register for Health Care.

266 We considered nine covariates as confounders in our study: age group, region of residency, sex (Population
267 Information System), hospitalisation between 1 September 2021 and 31 August 2022 (Care Register for
268 Health Care), presence of comorbidities or medical therapies predisposing to severe COVID-19 (Care
269 Register for Health Care, Register of Primary Health Care visits, Special Reimbursement Register for
270 Medicine Expenses and Prescription Centre database, residency in a long-term care facility (Care Register
271 for Social Care), seasonal influenza vaccination in 2022–2023, number of monovalent COVID-19
272 vaccinations (Finnish Vaccination Register) and last laboratory-confirmed SARS-CoV-2 infection prior to the
273 study (National Infectious Diseases Register). Previous SARS-CoV-2 infections were categorised into pre-
274 Omicron infections (before 2022) and Omicron infections (since 2022).


275 The individual follow-up period started earliest on 1 September 2022 and latest 91 days after the last
276 monovalent COVID-19 vaccination or laboratory-confirmed SARS-CoV-2 infection prior to the study. Each

277 individual was followed until death, outcome of interest, day 14 (if the outcome of interest was
278 hospitalisation due to COVID-19) or day 60 after laboratory-confirmed SARS-CoV-2 infection, a second
279 bivalent vaccination, a monovalent vaccination and 31 March 2023, whichever occurred first.

280 Separately for the two calendar periods September–December 2022 and January–March 2023 and for each
281 cohort, we compared the hazard of the three severe COVID-19 outcomes between unexposed and exposed
282 individuals taking into account time since bivalent vaccination. The hazard ratio (HR) was estimated using
283 Cox regression with calendar time as the underlying time scale and adjusted for the aforementioned
284 covariates. Additionally, we stratified the elderly cohort by age differentiating between individuals aged
285 65–79 years and those aged 80 years or more and analysed the HR separately for BA.1 and BA.4-5 bivalent
286 vaccines. For these analyses, we combined the second and third, fourth and fifth, and sixth and seventh
287 time since vaccination interval to account for the expectably small number of cases in these exposure
288 groups.

289 To evaluate the presence of residual confounding, we estimated the hazard ratio for the negative control
290 outcome and expected to find no difference between the unexposed and exposed. The analysis was
291 conducted as described above considering the negative control outcome as the outcome of interest. All
292 analyses were performed in R 4.2.2 (R Foundation for Statistical Computing, Vienna, Austria).

- Hospitalisation due to COVID-19
- △ Death due to COVID-19
- ▽ Death in which COVID-19 was a contributing factor



- ◊ Hospitalisation due to COVID-19
- △ Death due to COVID-19
- ▽ Death in which COVID-19 was a contributing factor

